NR1H4 ameliorates Parkinson’s disease via inhibiting astrocyte activation and neuroinflammation in a CEBPβ/NF-κB dependent manner
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113087 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jingwen Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China. Hauptthemen laut MEDLINE: Parkinson Disease, Receptors, Cytoplasmic and Nuclear, Astrocytes, CCAAT-Enhancer-Binding Protein-beta. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Parkinson's Disease (PD) is a degenerative disease driven by neuroinflammation. Nuclear receptor subfamily 1 group H member 4 (NR1H4), a nuclear receptor involved in metabolic and inflammatory regulation, is found to be widely expressed in central nervous system. Previous studies suggested the protective role of NR1H4 in various diseases related to inflammation, whether NR1H4 participates in PD progression remains unknown. To investigate the role of NR1H4 in neuroinflammation regulation, especially astrocyte activation during PD, siRNA and adenovirus were used to manipulate Nr1h4 expression. RNA-sequencing (RNA-seq), quantitative real-time PCR, enzyme-linked immunosorbent assay, Chromatin immunoprecipitation and western blotting were performed to further study the underlying mechanisms. We identified that NR1H4 was down-regulated during PD progression. In vitro experiments suggested that Nr1h4 knockdown led to inflammatory response, reactive oxygen species generation and astrocytes activation whereasNr1h4 overexpressionhad the opposite effects. The results of RNA-seq on astrocytes revealed that NR1H4 manipulated neuroinflammation in a CEBPβ/NF-κB dependent manner. Additionally, pharmacological activation of NR1H4 via Obeticholic acid ameliorated neuroinflammation and promoted neuronal survival. Our study first proved the neuroprotective effects of NR1H4against PD via inhibiting astrocyte activation and neuroinflammation in a CEBPβ/NF-κB dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China.
- Wuhan Red Cross Hospital, Wuhan, Hubei, China.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China. Electronic address: wangtaowh@hust.edu.cn.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China. Electronic address: nianxiong@hust.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Liu, H., Hu, X., Zhang, S., Yu, Q., Kuang, G., Liu, L., Yu, D., Huang, J., Xia, Y., Wang, T., & Xiong, N. (2024). NR1H4 ameliorates Parkinson’s disease via inhibiting astrocyte activation and neuroinflammation in a CEBPβ/NF-κB dependent manner. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113087
Vancouver
Li J, Liu H, Hu X, Zhang S, Yu Q, Kuang G, et al. NR1H4 ameliorates Parkinson’s disease via inhibiting astrocyte activation and neuroinflammation in a CEBPβ/NF-κB dependent manner. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113087
BibTeX
@article{Li2024,
author = {Li, Jingwen and Liu, Hanshu and Hu, Xinyu and Zhang, Shurui and Yu, Qinwei and Kuang, Guiying and Liu, Long and Yu, Danfang and Huang, Jinsha and Xia, Yun and Wang, Tao and Xiong, Nian},
title = {NR1H4 ameliorates Parkinson’s disease via inhibiting astrocyte activation and neuroinflammation in a CEBPβ/NF-κB dependent manner},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113087}
}
EUVIMED